Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction
Autor: | Giuseppina Novo, Silvia Sarullo, Cinzia Nugara, Francesco Giallauria, Filippo M. Sarullo, Valentina Agnese, Giuseppe Romano, Laura Ajello, Antonino Di Franco, Salvo Storniolo, Giuseppa Caccamo, Francesco Clemenza, Giuseppe Vitale |
---|---|
Přispěvatelé: | Vitale, G, Romano, G, Di Franco, A, Caccamo, G, Nugara, C, Ajello, L, Storniolo, S, Sarullo, S, Agnese, V, Giallauria, F, Novo, G, Clemenza, F, Sarullo, Fm., Vitale, Giuseppe, Romano, Giuseppe, Di Franco, Antonino, Caccamo, Giuseppa, Nugara, Cinzia, Ajello, Laura, Storniolo, Salvo, Sarullo, Silvia, Agnese, Valentina, Giallauria, Francesco, Novo, Giuseppina, Clemenza, Francesco, Sarullo, Filippo M |
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
Oxygen pulse lcsh:Medicine heart failure 030204 cardiovascular system & hematology Article Sacubitril 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine Ejection fraction business.industry lcsh:R General Medicine medicine.disease Blood pressure Valsartan Heart failure sacubitril/valsartan Cardiology exercise tolerance business Anaerobic exercise Sacubitril Valsartan medicine.drug cardiopulmonary test |
Zdroj: | Journal of Clinical Medicine, Vol 8, Iss 2, p 262 (2019) Journal of Clinical Medicine Volume 8 Issue 2 |
Popis: | Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with HFrEF. Methods. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in addition to recommended therapy. Results. At baseline, 37% of patients had New York Heart Association (NYHA) class III. After a median follow-up of 6.2 months (range 3&ndash 14.9 months) systolic blood pressure decreased from 117 ± 14 to 101 ± 12 mmHg (p < 0.0001), left ventricular ejection fraction (LVEF) increased from 27 ± 6 to 29.7 ± 7% (p < 0.0001), peak oxygen consumption (VO2) improved from 14.6 ± 3.3 (% of predicted = 53.8 ± 14.1) to 17.2 ± 4.7 mL/kg/min (% of predicted = 64.7 ± 17.8) (p < 0.0001), minute ventilation/carbon dioxide production relationship (VE/VCO2 Slope) decreased from 34.1 ± 6.3 to 31.7 ± 6.1 (p = 0.006), VO2 at anaerobic threshold increased from 11.3 ± 2.6 to 12.6 ± 3.5 mL/kg/min (p = 0.007), oxygen pulse increased from 11.5 ± 3.0 to 13.4 ± 4.3 mL/kg/min (p < 0.0001), and ∆VO2/∆Work increased from 9.2 ± 1.5 to 10.1 ± 1.8 mL/min/watt (p = 0.0002). Conclusion. Sacubitril/valsartan improved exercise tolerance, LVEF, peak VO2, and ventilatory efficiency at 6.2 months follow-up. Further studies are necessary to better clarify underlying mechanisms of this functional improvement. |
Databáze: | OpenAIRE |
Externí odkaz: |